Home / Publications / Pain Research Forum / Papers of the Week / [Tapentadol versus classical WHO-III opioids for chronic back pain. Health services research study based on representative data from health insurance funds].
[Tapentadol versus classical WHO-III opioids for chronic back pain. Health services research study based on representative data from health insurance funds].
In clinical trials, tapentadol prolonged release (PR) showed a more favourable gastrointestinal tolerability profile compared to other strong opioids in the treatment of pain. The present analysis compared tapentadol PR and classical WHO-III PR opioids in routine clinical practice.
